The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - Achilles Therapeutics; Amgen; AstraZeneca; Bayer; Bristol-Myers Squibb/Celgene; Celgene; EQRx; Immutep; Janssen Oncology; Lilly; Merck Serono; Merck Sharp & Dohme; Oxford VacMedix; Pfizer; PharmaMar; Roche; Takeda; Transgene; UltraHuman
Research Funding - Boehringer Ingelheim (Inst); Merck Serono (Inst); MSD Oncology (Inst)
Travel, Accommodations, Expenses - Achilles Therapeutics; AstraZeneca; Bristol-Myers Squibb; Celgene; Immutep; Janssen Oncology; MSD Oncology; Roche
FURTHER: A global study to evaluate furmonertinib in patients with EGFR mutant NSCLC including uncommon EGFR mutations (FURMO-002).
 
Xiuning Le
Stock and Other Ownership Interests - BlossomHill Therapeutics
Consulting or Advisory Role - Abbvie; ABION; ArriVent Biopharma; AstraZeneca; Bayer; Blueprint Medicines; Boehringer Ingelheim; Daiichi Sankyo/Lilly; EMD Serono; Hengrui Therapeutics; Janssen Oncology; Lilly; Novartis; Regeneron; Sensei Biotherapeutics; Spectrum Pharmaceuticals; Systimmune; Taiho Pharmaceutical
Research Funding - ArriVent Biopharma (Inst); Boehringer Ingelheim (Inst); EMD Serono (Inst); Janssen (Inst); Lilly (Inst); Regeneron (Inst); Teligene (Inst)
Travel, Accommodations, Expenses - EMD Serono; Spectrum Pharmaceuticals
 
Alexander I. Spira
Leadership - Next Oncology (Inst)
Stock and Other Ownership Interests - Lilly
Honoraria - Amgen; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; CytomX Therapeutics; Janssen Oncology; Merck; Novartis; Takeda
Consulting or Advisory Role - Amgen; Array BioPharma (Inst); AstraZeneca/MedImmune (Inst); AstraZeneca/MedImmune (Inst); Black Diamond Therapeutics; Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo/Astra Zeneca; Gritstone Bio; Gritstone Bio; incyte; Janssen Research & Development; Jazz Pharmaceuticals; Lilly; Merck (Inst); Mersana; Mirati Therapeutics; Novartis; Regeneron; Sanofi; Sanofi; Takeda
Research Funding - Abbvie (Inst); ADC Therapeutics (Inst); ADC Therapeutics (Inst); Alkermes (Inst); Amgen (Inst); Arch Therapeutics (Inst); ArriVent Biopharma (Inst); Astellas Pharma (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); Black Diamond Therapeutics (Inst); Blueprint Medicines (Inst); BluPrint Oncology (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Gritstone Bio (Inst); Ignyta (Inst); Incyte (Inst); Janssen Oncology (Inst); LAM Therapeutics; Loxo (Inst); Loxo (Inst); Macrogenics (Inst); Medikine (Inst); MedImmune (Inst); mersana (Inst); Mirati Therapeutics (Inst); nalo therapeutics (Inst); Novartis (Inst); Plexxikon (Inst); Regeneron; Revolution Medicines (Inst); Revolution Medicines (Inst); Roche (Inst); Rubius Therapeutics (Inst); Scorpion Therapeutics (Inst); Synthekine (Inst); Synthekine (Inst); Takeda (Inst)
 
Shirish M. Gadgeel
Honoraria - Merck
Consulting or Advisory Role - Arcus Biosciences; AstraZeneca; Bayer; Blueprint Medicines; Bristol-Myers Squibb; Daichii-Sanyko; Eisai; Genentech/Roche; Gilead Sciences; GlaxoSmithKline; Janssen Oncology; Lilly; Merck; Mirati Therapeutics; Novartis; Pfizer; Regeneron; Takeda
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca; AstraZeneca (Inst); BioMed Valley Discoveries (Inst); Blueprint Medicines (Inst); Calithera Biosciences (Inst); Daichii Sanyko (Inst); Daiichi Sankyo (Inst); Debiopharm Group (Inst); Dragonfly Therapeutics (Inst); eFFECTOR Therapeutics (Inst); Elevation Oncology (Inst); Erasca, Inc (Inst); Genentech/Roche (Inst); Helsinn Therapeutics (Inst); I-Mab (Inst); Incyte (Inst); InventisBio (Inst); Janssen Oncology (Inst); Merck; Merck (Inst); Mirati Therapeutics (Inst); Nektar (Inst); Nektar (Inst); Numab (Inst); Pfizer (Inst); Regeneron (Inst); Regeneron (Inst); Turning Point Therapeutics (Inst); Verastem (Inst); Ymabs Therapeutics Inc (Inst)
Travel, Accommodations, Expenses - Mirati Therapeutics
Other Relationship - AstraZeneca
 
Jonathan W. Riess
Consulting or Advisory Role - Amgen; Bayer; BeiGene; Biodesix; Boehringer Ingelheim; Bristol-Myers Squibb/Celgene; Catalyst Clinical Research; Daiichi Sankyo; EMD Serono; Genentech; Janssen Oncology; Merck; Merus NV; Novartis; OncoCyte; Regeneron; Sanofi; Seagen; Turning Point Therapeutics
Research Funding - ArriVent Biopharma (Inst); AstraZeneca/MedImmune (Inst); Boehringer Ingelheim (Inst); IO Biotech (Inst); Kinnate Biopharma (Inst); Merck (Inst); Novartis (Inst); Revolution Medicines (Inst); Spectrum Pharmaceuticals (Inst); Summit pharmaceuticals (Inst)
Travel, Accommodations, Expenses - AstraZeneca; IO Biotech
 
Yan Yu
No Relationships to Disclose
 
Yanqiu Zhao
No Relationships to Disclose
 
Ying Cheng
No Relationships to Disclose
 
Oscar Juan-Vidal
Honoraria - Amgen; AstraZeneca/MedImmune; Janssen; Takeda
Consulting or Advisory Role - AstraZeneca Spain; Janssen Oncology; Lilly; Takeda
Research Funding - AstraZeneca Spain (Inst)
Travel, Accommodations, Expenses - AstraZeneca/MedImmune; Pfizer; Roche/Genentech; Takeda
 
Bo Gao
Consulting or Advisory Role - BeiGene; IMPAC Medical Systems; IMPAC Medical Systems; MSD
 
Kiyotaka Yoh
Honoraria - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; MSD; Ono Pharmaceutical; Takeda
Consulting or Advisory Role - Boehringer Ingelheim
Research Funding - Abbvie (Inst); ArriVent Biopharma (Inst); AstraZeneca (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Lilly Japan (Inst); MSD (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Martin Forster
No Relationships to Disclose
 
Satoru Kitazono
Honoraria - AstraZeneca; Chugai Pharma; Ono Pharmaceutical; Pfizer
 
Hidetoshi Hayashi
Honoraria - 3H Clinical Trial; Amgen; AstraZeneca Japan; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo/UCB Japan; Guardant Health; Janssen; Lilly; Merck; MSD K.K; Nippon Boehringer Ingelheim; Novartis; Ono Pharmaceutical; Pfizer; Sysmex; Takeda
Consulting or Advisory Role - Abbvie; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo/UCB Japan; Janssen; Novocure K.K.
Research Funding - A2 Healthcare (Inst); Abbvie (Inst); Amgen (Inst); Ascent Development Services (Inst); Astellas Pharma (Inst); AstraZeneca Japan (Inst); Bayer Yakuhin (Inst); Bristol Myers Squibb Company (Inst); Chugai Pharma (Inst); CMIC CO., Ltd. (Inst); Daiichi Sankyo Co., Ltd. (Inst); Eisai (Inst); Eisai (Inst); EPS Holdings (Inst); EPS Holdings (Inst); GlaxoSmithKline K.K. (Inst); IQVIA Services JAPAN K.K (Inst); Janssen (Inst); Kobayashi Pharmaceutical (Inst); Kyowa Kirin Co., Ltd (Inst); Labcorp Drug Development (Inst); Lilly Japan (Inst); Medpace Japan KK (Inst); Merck (Inst); MSD K.K. (Inst); Nippon Boehringer Ingelheim (Inst); Nippon Kayaku (Inst); Novartis (Inst); Otsuka (Inst); Pfizer (Inst); Pfizer (Inst); PRA Health Sciences Inc. (Inst); Sanofi (Inst); Shionogi (Inst); SRL Medisearch Inc. (Inst); Syneos Health (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
Patents, Royalties, Other Intellectual Property - Sysmex
 
David Planchard
Honoraria - PeerVoice; Prime Oncology
Consulting or Advisory Role - Abbvie; Anheart Therapeutics; AstraZeneca; BeiGene; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Daiichi Sankyo/Astra Zeneca; Gilead Sciences; Janssen; MSD Oncology; Novartis; Pfizer; Pierre Fabre; Roche; Samsung; Seagen
Research Funding - Abbvie (Inst); AstraZeneca/MedImmune (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); Janssen (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Pierre Fabre (Inst); Roche (Inst); Sanofi/Aventis (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst)
 
Yong Jiang
Employment - Allist Pharmaceuticals
Stock and Other Ownership Interests - Allist Pharmaceuticals
 
Nichole Baio
Employment - ArriVent Biopharma
Stock and Other Ownership Interests - ArriVent Biopharma
 
Marcin Kowanetz
Employment - ArriVent Biopharma
Stock and Other Ownership Interests - ArriVent Biopharma; Bolt Biotherapeutics
Patents, Royalties, Other Intellectual Property - Bolt Biotherapeutics
 
William Leung
Employment - ArriVent Biopharma; Genentech
Stock and Other Ownership Interests - Roche/Genentech
Travel, Accommodations, Expenses - ArriVent Biopharma; Genentech
 
Jerry Y. Hsu
Employment - ArriVent Biopharma
Stock and Other Ownership Interests - ArriVent Biopharma; Genentech
 
Jie Wang
No Relationships to Disclose